TNFRSF17 and myasthenia gravis: ,13 The trial of anti-BCMA RNA CAR T cells (rCAR-T) in myasthenia gravis in part 2 showed that 89% of participants had ≥2-point improvement in MG-ADL score, and 56% had ≥6-point improvement.12